to us as of the filing date of this Form 10-K, and we undertake no obligation to update or revise any of these forward-looking statements for any reason, whether as a result of new information, future events or otherwise after the date of this Form 10-K, except as required by law. ...
View: Download DOC Download PDF Download XLS Download XBRL
For this purpose, the “relevant date” in relation to any Note means the later of (a) the due date for such payment or (b) the date such payment was made or duly provided for; (iii) in respect of any Taxes that would not have been imposed, deducted or withheld but for a ...
“ABL Collateral Agent” means Morgan Stanley Senior Funding, Inc., as administrative agent and a co-collateral agent for the holders of the ABL Debt Obligations, and, from and after the date of execution and delivery of any substitute facility, the agent, collateral agent, trustee or other r...
Assets held for sale 8,869 8,790 Other assets 1,313 778 Total Assets $ 30,190 $ 31,801 LIABILITIES AND EQUITY Accounts payable $ 984 $ 1,001 Accrued expenses and other liabilities 1,009 1,033 Deferred tax liability 896 924 Unreali...
Next Reset May 2024 N/A N/A N/A N/A(1) For the second through fifth lease years, after which time the annual escalation becomes 1.75% for the 6th and 7th lease years and then 2% for the remaining term of the lease. (2) Increases by 1.5% on the opening date (which occurred on...
A summary of restricted stock, restricted stock units, and performance share award activity for the three month period ended April 29, 2023, is presented below: (000, except per share data) Number of shares Weighted-averagegrant datefair value Unvested at January 28, 2023 3,943 $ 99.69 ...
This has the effect of limiting the ability of a potential acquirer to make a two-tiered bid for the target in which all shareholders would not be treated equally. The statute does not apply if, among other things, prior to the date on which such shareholder becomes an interested ...
View: Download DOC Download PDF Download XLS Download XBRL
PBGENE-PMM holds the potential to deliver a one-time, transformative treatment for patients with primary mitochondrial myopathy (PMM),” said Jeff Smith, Co-Founder and Chief Research Officer. “Together with PBGENE-HBV, we believe that both of these programs are emblematic of the unique ...